Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV breast cancer that is unlikely to respond to existing therapy and for which no curative therapy exists~  * Must have failed prior standard therapy~* Measurable disease by MRI or CT scan~* Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in other locations~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal Status:~* Not specified~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin nor greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious medical or psychiatric disorders~* No active infections~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy, except in patients with disease progression during or after initial therapy~* Recovery from prior immunotherapy~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas), except in patients with disease progression during or after initial therapy~* Recovery from prior chemotherapy~* No concurrent antineoplastic agents~Endocrine therapy:~* At least 12 weeks since prior hormonal therapy, except in patients with disease progression during and after initial therapy~* Concurrent corticosteroids allowed~* Recovery from prior hormonal therapy~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors who have received radiotherapy to some, but not all, tumors may be admitted earlier than 8 weeks)~Surgery:~* Recovered from any prior surgery~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agent allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues